Search
Selected Filter
Displaying 1–10 of 158 research results
-
First Patient Receives AON Therapy for LCA10 in ProQR’s Phase 2/3 Clinical Trial
The treatment, formerly known as QR-110, is designed for people with the retinal disease Leber congenital amaurosis 10
-
First Gene Therapy for Dry AMD Moves into Clinical Trial in UK
Gyroscope Therapeutics, a gene-therapy development company in the UK, has launched the first gene therapy clinical trial for the dry form of age-related macular degeneration (AMD).
-
First Patient Receives ProQR’s Emerging USH2A Therapy in Clinical Trial
ProQR, a developer of RNA therapies in the Netherlands, announced that the first clinical-trial participant has received its emerging treatment, which targets retinitis pigmentosa and Usher syndrome caused by mutations in exon 13 of the USH2A gene.
-
Encouraging Vision Improvements Reported in ReNeuron's Cell-Therapy Clinical Trial
ReNeuron, a cellular therapy developer in the UK, has reported vision improvements in the treated eyes of the first three retinitis pigmentosa (RP) patients in the Phase II part of the Phase I/II clinical trial for its proprietary human retinal progenitor cells (hRPC). The Phase I portion of the trial, completed last year, primarily assessed safety in subjects with minimal remaining vision.
-
Usher Syndrome Research Advances
Recent developments in research on Usher Syndrome.
-
Stargardt Disease Research Advances
Recent developments in research on Stargardt disease
-
Leber Congenital Amaurosis Research Advances
Recent developments in research on Leber congenital amaurosis
-
Age-Related Macular Degeneration Research Advances
Recent developments in research on age-related macular degeneration.
-
Retinitis Pigmentosa Research Advances
Recent developments in research on retinitis pigmintosa.
-
The Foundation Receives a $100,000 Research Grant from Sofia Sees Hope
Sofia Sees Hope, a nonprofit dedicated to finding treatments and cures for people with Leber congenital amaurosis (LCA) and other inherited retinal diseases (IRDs), has made a $100,000 donation to the Foundation Fighting Blindness to support therapy development and genetic testing.
